Back

Non-canonical induction of autophagy increases adeno-associated virus type 2 (AAV2) transduction efficiency

Sutter, S. O.; Jetzer, S.; Lkharrazi, A.; Pedersen, S.; Schraner, E. M.; Vogt, B.; Büning, H.; Fraefel, C.

2024-01-11 microbiology
10.1101/2024.01.08.574727 bioRxiv
Show abstract

Adeno-associated virus (AAV) serotypes infect a wide range of cell types, making this member of the parvovirus family a versatile tool in gene therapy. Infection as well as transduction is set in motion by means of specific receptors in conjunction with trafficking pathways, particularly endocytosis, a main cell entry pathway of non-enveloped viruses. Here, we report that efficacy of transduction is enhanced upon treating cells with hyperosmotic sucrose, a known blocker of clathrin-mediated endocytosis, through the non-canonical induction of autophagy. This mechanism of autophagy induction, however, is different from the previously reported AAV2-mediated induction of autophagy, which relies on a canonical, phosphoinositide 3-kinase class III (PI3K-III) complex-dependent pathway and appears to be dependent on the virus intrinsic secreted phospholipase A2 (sPLA2) domain, particularly its catalytic center activity. IMPORTANCEAdeno-associated virus (AAV) vectors are among the most frequently applied virus-based delivery vehicles for gene therapy. Lack of pathogenicity for humans, availability of a huge number of AAV serotypes differing in their cellular tropism, and the mainly episomal persistence of AAV vector genomes are clear advantages of these biological nanoparticles. By exploring non-pharmacological inducers of autophagy, we provide evidence for a potent and easy to apply strategy to significantly improve the efficacy of recombinant AAV-based gene delivery in hepatic and structural cells. Besides, our data also demonstrate the importance of autophagy for AAV2 infection and vector-mediated transduction in non-hepatic cells.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
23.7%
2
Nature Communications
4913 papers in training set
Top 25%
7.2%
3
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.2%
2.7%
4
Autophagy
32 papers in training set
Top 0.1%
2.2%
5
Scientific Reports
3102 papers in training set
Top 48%
2.2%
6
ACS Synthetic Biology
256 papers in training set
Top 1%
2.2%
7
Molecular Therapy
71 papers in training set
Top 1%
2.2%
8
Journal of Virology
456 papers in training set
Top 2%
2.0%
9
iScience
1063 papers in training set
Top 11%
2.0%
10
eLife
5422 papers in training set
Top 38%
1.9%
11
PLOS Biology
408 papers in training set
Top 9%
1.8%
50% of probability mass above
12
Nucleic Acids Research
1128 papers in training set
Top 10%
1.8%
13
EMBO reports
136 papers in training set
Top 2%
1.8%
14
Antiviral Research
49 papers in training set
Top 0.2%
1.8%
15
Advanced Science
249 papers in training set
Top 10%
1.8%
16
PLOS Pathogens
721 papers in training set
Top 6%
1.8%
17
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 34%
1.6%
18
mBio
750 papers in training set
Top 8%
1.4%
19
Cellular and Molecular Life Sciences
84 papers in training set
Top 0.3%
1.3%
20
Cancers
200 papers in training set
Top 4%
1.0%
21
Viruses
318 papers in training set
Top 4%
1.0%
22
Journal of Medical Virology
137 papers in training set
Top 3%
0.9%
23
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.6%
0.9%
24
Frontiers in Microbiology
375 papers in training set
Top 7%
0.9%
25
Cell Death & Disease
126 papers in training set
Top 2%
0.8%
26
PLOS ONE
4510 papers in training set
Top 65%
0.8%
27
Emerging Microbes & Infections
74 papers in training set
Top 1%
0.8%
28
Cell Reports Medicine
140 papers in training set
Top 7%
0.8%
29
ACS Nano
99 papers in training set
Top 3%
0.8%
30
Metabolic Engineering
68 papers in training set
Top 0.6%
0.8%